Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial

BACKGROUND: Immune checkpoint inhibitors monotherapy has been studied in patients with advanced biliary tract cancer (BTC). The aim of this study was to assess the efficacy and safety of camrelizumab, plus gemcitabine and oxaliplatin (GEMOX) as first-line treatment in advanced BTC and explored the p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Immunother Cancer
Hlavní autoři: Chen, Xiaofeng, Wu, Xiaofeng, Wu, Hao, Gu, Yanhong, Shao, Yang, Shao, Qianwen, Zhu, Feipeng, Li, Xiao, Qian, Xiaofeng, Hu, Jun, Zhao, Fengjiao, Mao, Weidong, Sun, Jing, Wang, Jian, Han, Gaohua, Li, Changxian, Xia, Yongxiang, Seesaha, Poshita Kumari, Zhu, Dongqin, Li, Huajun, Zhang, Junling, Wang, Guoqiang, Wang, Xuehao, Li, Xiangcheng, Shu, Yongqian
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2020
Témata:
Clinical/Translational Cancer Immunotherapy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7656907/
https://ncbi.nlm.nih.gov/pubmed/33172881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001240
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky